Evidence map›Paper›PMID 27487123›Full record

ArticleOncotarget2017

KDM4B-mediated epigenetic silencing of miRNA-615-5p augments RAB24 to facilitate malignancy of hepatoma cells.

Zheng Chen, Xiangling Wang, Ruiyan Liu, Lin Chen, Jianying Yi, Bing Qi, Zeyu Shuang, Min Liu, Xin Li, Shengping Li and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Emerging roles of JMJD3 in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Role of Rab GTPases in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2021
    Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Zheng ChenTianjin Life Science Research Center and School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Xiangling WangTianjin Life Science Research Center and School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Ruiyan LiuTianjin Life Science Research Center and School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Lin ChenTianjin Life Science Research Center and School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Jianying YiTianjin Life Science Research Center and School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Bing QiTianjin Life Science Research Center and School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Zeyu ShuangState Key Laboratory of Oncology in Southern China, Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China.
Min LiuTianjin Life Science Research Center and School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Xin LiTianjin Life Science Research Center and School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Shengping LiState Key Laboratory of Oncology in Southern China, Department of Hepatobiliary Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, China.
Hua TangTianjin Life Science Research Center and School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Tianjin Medical University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence indicates that dysregulation of microRNAs (miRNAs) contributes to hepatocellular carcinoma (HCC) tumorigenesis and development. Here, we found that miR-615-5p was obviously downregulated in HCC. Furthermore, the deficiency of demethylase KDM4B stimulated the CpG methylation of miR-615-5p promoter and then decreased the miR-615-5p expression. The Ras-related protein RAB24 was found to be downregulated by miR-615-5p. The low level of miR-615-5p increased the expression of RAB24 and facilitated HCC growth and metastasis in vitro and in vivo. Moreover, miR-615-5p suppresses HCC cell growth by influencing cell cycle progression and apoptosis. Downregulation of miR-615-5p and upregulation of RAB24 promotes the epithelial-mesenchymal transition (EMT), adhesion and vasculogenic mimicry (VM) of HCC cells, all of which contribute to cell motility and metastasis. Thus, miR-615-5p, who is downregulated by KDM4B-mediated hypermethylation in its promoter, functions as a tumor suppressor by inhibiting RAB24 expression in HCC. In conclusion, our findings characterize miR-615-5p as an important epigenetically silenced miRNA involved in the Rab-Ras pathway in hepatocellular carcinoma and expand our understanding of the molecular mechanism underlying hepatocarcinogenesis and metastasis.

Indexed as

ApoptosisCarcinoma, HepatocellularCell AdhesionCell CycleCell Line, TumorCell MovementCell ProliferationCpG IslandsDNA MethylationDown-RegulationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHep G2 CellsHumansJumonji Domain-Containing Histone DemethylasesLiver NeoplasmsJumonji Domain-Containing Histone DemethylasesKDM4B protein, humanMicroRNAsMIRN615 microRNA, humanRAB24 protein, humanrab GTP-Binding ProteinsDNA methylationgene regulationHCCmetastasismiRNAs

Identifiers

PMID27487123
PMCPMC5392280
OpenAlexW2496036016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.